Zusammenfassung
Die akute Lungenembolie ist die dritthäufigste akute kardiovaskuläre Erkrankung und geht mit einer durchschnittlichen Letalitätsrate von bis zu 10% innerhalb der ersten 3 Monate einher. Themen dieses Übersichtsartikels sind insbesondere die risikoadaptierte Diagnostik und Therapie der akuten Lungenembolie.
Abstract
Acute pulmonary embolism (PE) is the third most frequent acute cardiovascular disease with an overall annual incidence of 100 – 200 cases per 100.000 population and a high mortality rate of up to 10% over the first 3 months after diagnosis. This article summarises and critically discusses the recommendations of current guidelines and the most relevant recent data on risk stratification, reperfusion, and anticoagulation treatment of acute PE. We particularly focus on (i) the evolving definition of intermediate-risk PE and its implications for initial treatment; (ii) advances in pharmacological and catheter-directed thrombus lysis; and (iii) the benefits versus risks of extended, indefinite anticoagulation after PE based on the available tools for assessment of the patientʼs recurrence versus bleeding risk.
Schlüsselwörter
Lungenembolie - Risikostratifizierung - Thrombolyse - Antikoagulation - Rezidiv - Blutung
Key words
pulmonary embolism - risk stratification thrombolysis - anticoagulation - PE recurrence - bleeding
